References
- Subherwal S, Bhatt DL, Li S, et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non–ST-segment–elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5(4):541–549.
- Shu J, Santulli G. Update on peripheral artery disease: epidemiology and evidence-based facts. Atherosclerosis. 2018;275:379–381.
- Mahoney EM, Wang K, Cohen DJ, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1(1):38–45.
- Smolderen KG, Bell A, Lei Y, et al. One-year costs associated with cardiovascular disease in Canada: insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Canadian J Cardiol. 2010;26(8):e297–e305.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
- Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330.
- Virani SS, Akeroyd JM, Smith SC, et al. Very high-risk ASCVD and eligibility for nonstatin therapies based on the 2018 AHA/ACC cholesterol guidelines. J Am Coll Cardiol. 2019;74(5):712–714.
- Kazi DS, Virani SS. Implications of cost-effectiveness analyses of lipid-lowering therapies: from the policy-maker’s desk to the patient’s bedside. Prog Cardiovasc Dis. 2019;62(5):406–413.
- Emery C, Torreton E, Briere JB, et al. Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis. J Med Econ. 2020. DOI:10.1080/13696998.2020.1715415
- Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet. 1996;348(9038):1329–1339.
- Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708.
- Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404–1413.
- Smolderen KG, Wang K, De Pouvourville G, et al. REACH Registry Investigators. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease. Euro J Vasc Endovasc Surg. 2012;43(2):198–207.
- McBride CL, Akeroyd JM, Ramsey DJ, et al. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: insights from the Department of Veterans Affairs. Vasc Med. 2018;23(3):232–240.
- Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018;137(4):338–350.
- Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229.
- Darmon A, Sorbets E, Ducrocq G, et al. Association of multiple enrichment criteria with ischemic and bleeding risks among COMPASS-eligible patients. J Am Coll Cardiol. 2019;73(25):3281–3291.
- Vanassche T, Verhamme P, Anand SS, et al. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: an analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiolog. 2020;27(3):296–307.
- Cowie MR, Lamy A, Levy P, et al. PCV51 Cost-effectiveness of Rivaroxaban in the treatment of patients with chronic CAD or PAD in the UK. Value in Health. 2019;22:S550.
- Ademi Z, Zomer E, Tonkin A, et al. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective. Int J Cardiol. 2018;270:54–59.